Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aubrey L Miller

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Pharmacological Research|March 6, 2020
Developing effective combination therapy for pancreatic cancer: An overviewAubrey L Miller, Patrick L Garcia, Karina J Yoon
Cancers|May 28, 2020
Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of ModelsPatrick L Garcia, Aubrey L Miller, Karina J Yoon
Cancer Letters|October 13, 2019
The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinomaSamuel C Fehling, Aubrey L Miller, Patrick L Garcia, et al.
Cancer Drug Resistance (Alhambra, Calif.)|October 19, 2020
Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinomaAubrey L Miller, Patrick L Garcia, Tracy L Gamblin, et al.
Cancer Drug Resistance (Alhambra, Calif.)|November 13, 2024
The BET inhibitor sensitivity is associated with the expression level of CDC25B in pancreatic cancer modelsAubrey L Miller, Patrick L Garcia, Rebecca B Vance, et al.
Frontiers in Oncology|July 7, 2022
The BET Inhibitor JQ1 Potentiates the Anticlonogenic Effect of Radiation in Pancreatic Cancer CellsPatrick L Garcia, Aubrey L Miller, Ling Zeng, et al.
Biotech (Basel (Switzerland))|February 21, 2025
Evaluating TcAs for Use in Biotechnology ApplicationsCole L Martin, John H Hill, Brian D Wright, et al.
Ebiomedicine|May 26, 2019
The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitorsAubrey L Miller, Samuel C Fehling, Patrick L Garcia, et al.
Scientific Reports|December 21, 2017
Whole exome sequencing identified sixty-five coding mutations in four neuroblastoma tumorsAubrey L Miller, Patrick L Garcia, Joseph G Pressey, et al.
Cancers|July 24, 2021
The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic CancerAubrey L Miller, Patrick L Garcia, Samuel C Fehling, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Pharmacological Research|March 6, 2020
Developing effective combination therapy for pancreatic cancer: An overviewAubrey L Miller, Patrick L Garcia, Karina J Yoon
Cancers|May 28, 2020
Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of ModelsPatrick L Garcia, Aubrey L Miller, Karina J Yoon
Cancer Letters|October 13, 2019
The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinomaSamuel C Fehling, Aubrey L Miller, Patrick L Garcia, et al.
Cancer Drug Resistance (Alhambra, Calif.)|October 19, 2020
Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinomaAubrey L Miller, Patrick L Garcia, Tracy L Gamblin, et al.
Cancer Drug Resistance (Alhambra, Calif.)|November 13, 2024
The BET inhibitor sensitivity is associated with the expression level of CDC25B in pancreatic cancer modelsAubrey L Miller, Patrick L Garcia, Rebecca B Vance, et al.
Frontiers in Oncology|July 7, 2022
The BET Inhibitor JQ1 Potentiates the Anticlonogenic Effect of Radiation in Pancreatic Cancer CellsPatrick L Garcia, Aubrey L Miller, Ling Zeng, et al.
Biotech (Basel (Switzerland))|February 21, 2025
Evaluating TcAs for Use in Biotechnology ApplicationsCole L Martin, John H Hill, Brian D Wright, et al.
Ebiomedicine|May 26, 2019
The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitorsAubrey L Miller, Samuel C Fehling, Patrick L Garcia, et al.
Scientific Reports|December 21, 2017
Whole exome sequencing identified sixty-five coding mutations in four neuroblastoma tumorsAubrey L Miller, Patrick L Garcia, Joseph G Pressey, et al.
Cancers|July 24, 2021
The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic CancerAubrey L Miller, Patrick L Garcia, Samuel C Fehling, et al.
Pageof 2